| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3748/WJG.V22.I44.9706 |
| P8608 | Fatcat ID | release_uennxdc2pjbvdk2qdbzoiai5xa |
| P932 | PMC publication ID | 5124975 |
| P698 | PubMed publication ID | 27956794 |
| P50 | author | Nada Pejnović | Q64433631 |
| Ilija Jeftic | Q86719097 | ||
| Nebojsa Arsenijevic | Q47155565 | ||
| Nemanja U Jovicic | Q61109629 | ||
| P2093 | author name string | Miodrag L Lukic | |
| P2860 | cites work | Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells | Q24530074 |
| Galectin-3 regulates myofibroblast activation and hepatic fibrosis | Q24546358 | ||
| Non-alcoholic fatty liver disease: what the clinician needs to know | Q24563068 | ||
| Insulin resistance in development and progression of nonalcoholic fatty liver disease | Q26748687 | ||
| Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis | Q26766533 | ||
| Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis | Q26771826 | ||
| The role of fatty acids in insulin resistance | Q26785440 | ||
| Lessons from mouse models of high-fat diet-induced NAFLD | Q26829532 | ||
| Role of cytokines and chemokines in non-alcoholic fatty liver disease | Q26830328 | ||
| The roles of Galectin-3 in autoimmunity and tumor progression | Q28261890 | ||
| Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease | Q28534290 | ||
| IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system | Q28585033 | ||
| IL-33 reduces the development of atherosclerosis | Q28594104 | ||
| Steatohepatitis: a tale of two "hits"? | Q29547771 | ||
| Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis | Q29619888 | ||
| Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation | Q33755829 | ||
| Reduction of galectin-3 expression and liver fibrosis after cell therapy in a mouse model of cirrhosis | Q34093510 | ||
| Endogenous lectins from cultured cells: nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts | Q34345937 | ||
| Cytokine receptors and signaling in hepatic stellate cells | Q34391388 | ||
| Galectin-3: an open-ended story | Q34494555 | ||
| Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice | Q34603941 | ||
| Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice | Q34626217 | ||
| Inflammatory links between obesity and metabolic disease | Q35015802 | ||
| Role of galectin-3 in diabetic nephropathy | Q35182376 | ||
| IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis | Q35250416 | ||
| Microglia-Secreted Galectin-3 Acts as a Toll-like Receptor 4 Ligand and Contributes to Microglial Activation. | Q35574021 | ||
| Differential Immunometabolic Phenotype in Th1 and Th2 Dominant Mouse Strains in Response to High-Fat Feeding | Q35720450 | ||
| Mechanisms Linking Inflammation to Insulin Resistance | Q35744922 | ||
| Inflammation as a Link between Obesity and Metabolic Syndrome | Q35864675 | ||
| Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis | Q36025690 | ||
| On the role of galectin-3 in cancer apoptosis | Q36103556 | ||
| When galectins recognize glycans: from biochemistry to physiology and back again | Q36196146 | ||
| Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice | Q36301170 | ||
| Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice | Q61903452 | ||
| Protective role of IL-33/ST2 axis in Con A-induced hepatitis | Q61903472 | ||
| The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins | Q73405607 | ||
| Liver fibrosis | Q80851925 | ||
| Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community | Q36439679 | ||
| Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication | Q36456913 | ||
| Detection of galectin-3 interaction with commensal bacteria. | Q36827014 | ||
| Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. | Q36887564 | ||
| Phosphorylation of IRS proteins, insulin action, and insulin resistance | Q37252616 | ||
| Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. | Q37311036 | ||
| Can Serum ST2 Levels Be Used as a Marker of Fibrosis in Chronic Hepatitis B Infection? | Q37328464 | ||
| IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis | Q37376114 | ||
| Hepatic inflammation and progressive liver fibrosis in chronic liver disease | Q37629675 | ||
| Mechanisms of hepatic fibrogenesis | Q37865859 | ||
| Defining macrophage phenotype and function in adipose tissue | Q37880478 | ||
| IL-33/ST2 axis in inflammation and immunopathology. | Q37990785 | ||
| The cellular and signaling networks linking the immune system and metabolism in disease | Q37991199 | ||
| Soluble ST2 and galectin-3 in heart failure | Q38186257 | ||
| Functions of galectin-3 and its role in fibrotic diseases | Q38246458 | ||
| Galectin-3: an emerging all-out player in metabolic disorders and their complications | Q38258947 | ||
| Galectin-3 stimulates cell proliferation | Q38330513 | ||
| ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel | Q38351562 | ||
| Interleukin 33 is a guardian of barriers and a local alarmin | Q38702558 | ||
| Galectin-3-induced cell spreading and motility relies on distinct signaling mechanisms compared to fibronectin | Q38774367 | ||
| Regulation of alternative macrophage activation by galectin-3. | Q40016366 | ||
| Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease | Q40751811 | ||
| High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma | Q40917751 | ||
| Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets | Q40944709 | ||
| IL-33 Reverses an Obesity-Induced Deficit in Visceral Adipose Tissue ST2+ T Regulatory Cells and Ameliorates Adipose Tissue Inflammation and Insulin Resistance. | Q41077951 | ||
| Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. | Q41322039 | ||
| Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis | Q41945735 | ||
| Galectin-3 is a regulator of metaflammation in adipose tissue and pancreatic islets | Q42624178 | ||
| Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis | Q43174499 | ||
| Do advanced glycation end products contribute to the development of long-term diabetic complications? | Q43458994 | ||
| Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. | Q44118879 | ||
| Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction | Q44245130 | ||
| Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure | Q44426645 | ||
| Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. | Q45052723 | ||
| Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation | Q46442221 | ||
| Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. | Q48024001 | ||
| Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. | Q52574179 | ||
| Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease. | Q55692292 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 44 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | human digestive system | Q9649 |
| peptide | Q172847 | ||
| Galectin 3 | Q3094567 | ||
| lectin | Q408693 | ||
| membrane protein | Q423042 | ||
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| steatohepatitis | Q2335423 | ||
| cell surface receptor | Q2476074 | ||
| physiological phenomenon | Q66615932 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 9706-9717 | |
| P577 | publication date | 2016-11-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis | |
| P478 | volume | 22 |
| Q94465802 | An Integrated Approach Exploring the Synergistic Mechanism of Herbal Pairs in a Botanical Dietary Supplement: A Case Study of a Liver Protection Health Food |
| Q98178483 | An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease |
| Q90073141 | Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases |
| Q47127784 | IL-33-ST2 Axis in Liver Disease: Progression and Challenge |
| Q55514878 | IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis. |
| Q53137711 | Inflammation and insulin resistance: New targets encourage new thinking: Galectin-3 and LTB4 are pro-inflammatory molecules that can be targeted to restore insulin sensitivity. |
| Q55308149 | Mice lacking galectin-3 (Lgals3) function have decreased home cage movement. |
| Q58745474 | NLRP3 Inflammasome and IL-33: Novel Players in Sterile Liver Inflammation |
| Q92162938 | Redefining Cirrhotic Cardiomyopathy for the Modern Era |
| Q89891175 | The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery |
| Q55353688 | Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases. |
Search more.